TrialBMC cancer2015

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.

Jean-Baptiste Bachet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.